Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John M. Quarles is active.

Publication


Featured researches published by John M. Quarles.


The Journal of Infectious Diseases | 2011

Early Patterns of Gene Expression Correlate With the Humoral Immune Response to Influenza Vaccination in Humans

Kristine L. Bucasas; Luis M. Franco; Chad A. Shaw; Molly S. Bray; Janet Wells; Diane Niño; Nancy H. Arden; John M. Quarles; Robert B. Couch; John W. Belmont

BACKGROUND Annual vaccination is the primary means for preventing influenza. However, great interindividual variability exists in vaccine responses, the cellular events that take place in vivo after vaccination are poorly understood, and appropriate biomarkers for vaccine responsiveness have not been developed. METHODS We immunized a cohort of healthy male adults with a licensed trivalent influenza vaccine and performed a timed assessment of global gene expression before and after vaccination. We analyzed the relationship between gene expression patterns and the humoral immune response to vaccination. RESULTS Marked up regulation of expression of genes involved in interferon signaling, positive IL-6 regulation, and antigen processing and presentation, were detected within 24 hours of immunization. The late vaccine response showed a transcriptional pattern suggestive of increased protein biosynthesis and cellular proliferation. Integrative analyses revealed a 494-gene expression signature--including STAT1, CD74, and E2F2--which strongly correlates with the magnitude of the antibody response. High vaccine responder status correlates with increased early expression of interferon signaling and antigen processing and presentation genes. CONCLUSIONS The results highlight the role of a systems biology approach in understanding the molecular events that take place in vivo after influenza vaccination and in the development of better predictors of vaccine responsiveness.


The Journal of Infectious Diseases | 2013

Antibody Correlates and Predictors of Immunity to Naturally Occurring Influenza in Humans and the Importance of Antibody to the Neuraminidase

Robert B. Couch; Robert L. Atmar; Luis M. Franco; John M. Quarles; Janet Wells; Nancy H. Arden; Diane Niño; John W. Belmont

BACKGROUND Serum antibody to the hemagglutinin (HA) of influenza viruses is a correlate and predictor of immunity to influenza in humans; the relative values of other correlates are uncertain. METHODS Serum and nasal secretions (NS) were collected in fall and spring of 2009-2011 from healthy adults who were monitored for acute respiratory illness (ARI). Serum samples were tested for hemagglutination-inhibition (HAI) antibody increase and secretions for virus if ill; enrollment sera were also tested for neuraminidase-inhibiting (NI) antibody and NS for neutralizing (neut), NI, immunoglobulin A (IgA), and immunoglobulin G (IgG) anti-HA antibody. RESULTS Serum anti-HA and anti-neuraminidase (NA) antibody titers to 2009(H1N1) pandemic influenza virus (pH1N1) correlated with titers in NS (including IgA and IgG antibody). Increasing anti-HA and anti-NA titers in serum and NS tests all correlated with reducing infection and infection-associated illness. Multivariate analyses indicated serum HAI and NI each independently predicted immunity to infection and infection-associated illness. Only serum NI independently predicted reduced illness among infected subjects. CONCLUSIONS Increasing anti-HA and NA antibody in serum and secretions correlated with reducing pH1N1 influenza virus infection and illness in healthy young adults. Both anti-HA and anti-NA antibody are independent predictors of immunity to influenza; ensuring induction of both by vaccination is desirable.


eLife | 2013

Integrative genomic analysis of the human immune response to influenza vaccination

Luis M. Franco; Kristine L. Bucasas; Janet Wells; Diane Niño; Xueqing Wang; Gladys Zapata; Nancy H. Arden; Alexander Renwick; Peng Yu; John M. Quarles; Molly S. Bray; Robert B. Couch; John W. Belmont; Chad A. Shaw

Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI: http://dx.doi.org/10.7554/eLife.00299.001


Vaccine | 2012

Randomized Comparative Study of the Serum Antihemagglutinin and Antineuraminidase Antibody Responses to Six Licensed Trivalent Influenza Vaccines

Robert B. Couch; Robert L. Atmar; Wendy A. Keitel; John M. Quarles; Janet Wells; Nancy H. Arden; Diane Niño

BACKGROUND Serum antibody to the hemagglutinin (HA) surface protein of influenza virus induced by influenza vaccination is a correlate of protection against influenza. The neuraminidase (NA) protein is also on the surface of the virus; antibody to it has been shown to impair virus release from infected cells and to reduce the intensity of influenza infections in animal models and in humans challenged with infectious virus. Recently we have shown that NA inhibiting antibody can independently contribute to immunity to naturally-occurring influenza immunity in the presence of antibody to the HA. PURPOSE The present study was conducted to evaluate induction of antibody to the NA and the HA by commercially available influenza vaccines. METHODS Healthy young adults were vaccinated with one of five commercially available trivalent inactivated vaccines or live influenza vaccine. Frequencies of serum antibody and fold geometric mean titer (GMT) increases four weeks later were measured to each of the three vaccine viruses (A/H1N1, A/H3N2, B) in hemagglutination-inhibition (HAI) and neutralization (neut) assays. Frequency and fold GMT increase in neuraminidase-inhibition (NI) antibody titers were measured to the influenza A viruses (A/H1N1, A/H3N2). RESULTS No significant reactogenicity occurred among the vaccinated subjects. The Fluvirin inactivated vaccine induced more anti-HA antibody responses and a higher fold GMT increase than the other inactivated vaccines but there were no major differences in response frequencies or fold GMT increase among the inactivated vaccines. Both the frequency of antibody increase and fold GMT increase were significantly lower for live vaccine than for any inactivated vaccine in HAI and neut assays for all three vaccine viruses. Afluria inactivated vaccine induced more N1 antibody and Fluarix induced more N2 antibody than the other vaccines but all inactivated vaccines induced serum NI antibody. The live vaccine failed to elicit any NI responses for the N2 NA of A/H3N2 virus and frequencies were low for the N1 of A/H1N1 virus. CONCLUSIONS Trivalent inactivated influenza vaccines with similar HA dosage induce similar serum anti-HA antibody responses in healthy adults. Current inactivated vaccines all induce serum anti-NA antibody to the N1 and N2 NA proteins but some are better than others for N1 or N2. The live vaccine, Flumist, was a poor inducer of either anti-HA or anti-NA serum antibody compared to inactivated vaccine in the healthy adults. In view of the capacity for contributing to immunity to influenza in humans, developing guidelines for NA content and induction of NA antibody is desirable.


PLOS Pathogens | 2015

Host Transcriptional Response to Influenza and Other Acute Respiratory Viral Infections – A Prospective Cohort Study

Yijie Zhai; Luis M. Franco; Robert L. Atmar; John M. Quarles; Nancy H. Arden; Kristine L. Bucasas; Janet Wells; Diane Niño; Xueqing Wang; Gladys Zapata; Chad A. Shaw; John W. Belmont; Robert B. Couch

To better understand the systemic response to naturally acquired acute respiratory viral infections, we prospectively enrolled 1610 healthy adults in 2009 and 2010. Of these, 142 subjects were followed for detailed evaluation of acute viral respiratory illness. We examined peripheral blood gene expression at 7 timepoints: enrollment, 5 illness visits and the end of each year of the study. 133 completed all study visits and yielded technically adequate peripheral blood microarray gene expression data. Seventy-three (55%) had an influenza virus infection, 64 influenza A and 9 influenza B. The remaining subjects had a rhinovirus infection (N = 32), other viral infections (N = 4), or no viral agent identified (N = 24). The results, which were replicated between two seasons, showed a dramatic upregulation of interferon pathway and innate immunity genes. This persisted for 2-4 days. The data show a recovery phase at days 4 and 6 with differentially expressed transcripts implicated in cell proliferation and repair. By day 21 the gene expression pattern was indistinguishable from baseline (enrollment). Influenza virus infection induced a higher magnitude and longer duration of the shared expression signature of illness compared to the other viral infections. Using lineage and activation state-specific transcripts to produce cell composition scores, patterns of B and T lymphocyte depressions accompanied by a major activation of NK cells were detected in the acute phase of illness. The data also demonstrate multiple dynamic gene modules that are reorganized and strengthened following infection. Finally, we examined pre- and post-infection anti-influenza antibody titers defining novel gene expression correlates.


Clinical Infectious Diseases | 2012

Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults

Robert B. Couch; Robert L. Atmar; Luis M. Franco; John M. Quarles; Diane Niño; Janet Wells; Nancy H. Arden; Sheree Cheung; John W. Belmont

Preexisting antibody, responses to seasonal and pandemic 2009 vaccine, a low infection-to-illness ratio, and shortened illnesses indicated preexisting immunity to pandemic H1N1 virus that caused the 2009 epidemic to be mild in healthy adults.


Vaccine | 2009

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Robert B. Couch; Robert L. Atmar; Thomas R. Cate; John M. Quarles; Wendy A. Keitel; Nancy H. Arden; Janet Wells; Diane Niño; Philip R. Wyde

To identify an adjuvant that enhances antibody responses in respiratory secretions to inactivated influenza virus vaccine (IVV), a comparison was made of responses to intranasal vaccinations of mice with IVV containing monophosphoryl lipid A (MPL), type I interferon (IFN) or cholera toxin B (CTB). Antibody in nasal secretions and lung wash fluids from mice was increased after vaccination and lung virus was significantly reduced after challenge to a similar level in each adjuvant group. Interferon was selected for a trial in humans. Trivalent inactivated influenza vaccine was given intranasally to healthy adult volunteers alone or with 1 million units (Mu) or 10 Mu of alpha interferon. Vaccinations were well tolerated but neither serum hemagglutination-inhibiting nor neutralizing antibody responses among the vaccine groups were significantly different. Similarly, neither neutralizing nor IgA antibody responses in nasal secretions were significantly different. Thus, despite exhibiting a significant adjuvant effect in mice, interferon did not exhibit an adjuvant effect for induction of antibody in respiratory secretions of humans to inactivated influenza virus vaccine given intranasally.


In Vitro Cellular & Developmental Biology – Plant | 1985

Cultivation of teratocytes of the egg parasitoid telenomus heliothidis (hymenoptera: Scelionidae)

M. R. Strand; John M. Quarles; S. M. Meola; S. B. Vinson

SummaryA method for in vitro cultivation of teratocytes from the egg parasitoidTelenomus heliothidis (Hymenoptera: Scelionidae) is described. Parasitoid eggs, from which teratocytes were derived, were collected from 24-h-oldHeliothis virescens (Lepidoptera: Noctuidae) eggs previously parasitized byT. heliothidis females. Optimal culture conditions, including species and concentration of serum, were determined experimentally. Thirty percentManduca sexta hemolymph or 10% chicken serum in Hink’s TNH-FH medium were found to generate the most satisfactory number of teratocytes per parasitoid larva. Teratocytes cultivated in vitro showed similar development and morphology to those produced in vivo. However, cultured teratocytes lived approximately 10 times longer than teratocytes in natural hosts and were not dependent upon the presence of the parasitoid larva for normal development.


The Journal of Infectious Diseases | 2001

Immunization against Influenza: Comparison of Various Topical and Parenteral Regimens Containing Inactivated and/or Live Attenuated Vaccines in Healthy Adults

Wendy A. Keitel; Thomas R. Cate; Diane Niño; Linda L. Huggins; Howard R. Six; John M. Quarles; Robert B. Couch

Methods for enhancing immune responses to influenza were explored in 2 double-blind, placebo-controlled trials. Intranasal (inl) immunization with monovalent, live attenuated, cold-adapted recombinant (CR) or inactivated influenza virus (MIV) vaccine and intramuscular (im) immunization with MIV were evaluated in various combinations. Healthy susceptible adults were assigned randomly to receive 10(7.1) TCID(50) of CR (A/H1N1 or A/H3N2), homologous MIV (15 microg), or placebo inl and placebo or homologous MIV im (6 groups in each study). Serum antibody responses were greatest in groups given im vaccine (with or without inl vaccine). A 2-fold increase in nasal wash antibody response frequencies was seen in groups given combined inl (CR or MIV) and im vaccine, compared with subjects given a single im (MIV) or inl (CR or MIV) vaccine. Combined inl and im immunization is a promising approach for enhancing both local and systemic immune responses against influenza.


Antiviral Research | 1981

Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza.

John M. Quarles; Robert B. Couch; Thomas R. Cate; Claude B. Goswick

The efficacies of 200 mg of daily doses of amantadine and of rimantadine for prevention of infection and illness due to influenza A/USSR/77 (H1N1) virus were compared in a double-blind, placebo-controlled study on a college campus. Frequencies of symptoms that might have been side effects of the drugs were not significantly different from those in placebo recipients. Analyses indicated that the trial was initiated late in the epidemic and that an age-related protective effect against A/USSR virus existed; seroconversion frequencies were 52/139 (37%) among 18-19-year-olds, 33/130 (25%) among 20-21-year-olds, and 5/39 (12.8%) among 22-24-year-olds. Among initially antibody-negative (less than 1 : 4 in complement fixing and neutralizing tests and less than 1 : 8 in hemagglutination inhibition tests) 18-19-year-old students, amantadine was associated with significantly fewer seroconversions (P = 0.01) and both less infection and milder illness than occurred in placebo recipients (P less than 0.05). Although rimantadine was not accompanied by reduction in frequency of seroconversions in the same age group, illness frequency and severity among seroconverters were significantly reduced when compared to placebo recipients (P less than 0.01). Amantadine and rimantadine appear suitable for use in young adults. Although other studies have suggested greater effectiveness of rimantadine than of amantadine against influenza, no evidence for this was seen in the present study which used both drugs at the same dose.

Collaboration


Dive into the John M. Quarles's collaboration.

Top Co-Authors

Avatar

Robert B. Couch

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Diane Niño

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Janet Wells

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

John W. Belmont

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Luis M. Franco

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Robert L. Atmar

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Thomas R. Cate

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Wendy A. Keitel

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Chad A. Shaw

Baylor College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge